Leonas Kalėtinas, executive director at the Lithuanian Innovative Pharmaceutical Industry Association (IFPA), explains the main dynamics impacting the innovative pharmaceutical industry in the country as well as some initiatives developed in collaboration with the national government to continue driving the Lithuanian pharmaceutical sector moving forward.
In 2014, the industry signed a “stability agreement” with authorities for the period running 2014-2017. What has been the most important result of this agreement?
"The market of clinical research is quite small in Lithuania, but the research-based players are being quite active in this front with clinical trial investments at approximately EUR 35 million."
